Effects of Angelica gigas Nakai as an Anti-Inflammatory Agent in In Vitro and In Vivo Atopic Dermatitis Models. (11th March 2018)

• Record Type: Journal Article
• Authors: Ok, Seon; Oh, Sa-Rang; Jung, Tae-Sung; Jeon, Sang-Ok; Jung, Ji-wook; Ryu, Deok-Seon
• Other Names: Xu Junji Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2018(2018)
• Publication Date: 2018-03-11
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2018/2450712
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : We investigated the cellular and molecular mechanisms mediating the effects of Angelica gigas Nakai extract (AGNE) through the mitogen-activated protein kinases (MAPKs)/NF- κ B pathway using in vitro and in vivo atopic dermatitis (AD) models. We examined the effects of AGNE on the expression of proinflammatory cytokines and chemokines in human mast cell line-1 (HMC-1) cells. Compound 48/80-induced pruritus and 2, 4-dinitrochlorobenzene- (DNCB-) induced AD-like skin lesion mouse models were also used to investigate the antiallergic effects of AGNE. AGNE reduced histamine secretion, production of proinflammatory cytokines including interleukin- (IL-) 1 β, IL-4, IL-6, IL-8, and IL-10, and expression of cyclooxygenase- (COX-) 2 in HMC-1 cells. Scratching behavior and DNCB-induced AD-like skin lesions were also attenuated by AGNE administration through the reduction of serum IgE, histamine, tumor necrosis factor- α (TNF- α ), IL-6 levels, and COX-2 expression in skin tissue from mouse models. Furthermore, these inhibitory effects were mediated by the blockade of the MAPKs and NF- κ B pathway. The findings of this study proved that AGNE improves the scratching behavior and atopy symptoms and reduces the activity of various atopy-related mediators in HMC-1 cells and mice model. These results suggest the AGNE has a therapeutic potential in anti-AD.